Introduction
Up to one third of people receiving antiepileptic drugs (AEDs) are women of reproductive age [1] and approximately 1 in 250 pregnancies are exposed to AEDs [2] . It is generally accepted that exposure to AED medications during pregnancy increases the risk of major congenital malformations (MCMs) from between 1-2% to between 4-9% [3] [4] [5] [6] [7] [8] [9] .
VPA was first licensed in 1978 for the management of a particular form of non-convulsive epilepsy called 'absence' epilepsy but anecdotally, it was found to be a useful treatment in a broad spectrum of seizure types and has thus been a commonly prescribed drug treatment for various forms of epilepsy for many years. The particularly high risk of MCMs with foetal exposure to VPA has been known for decades with first reports of Spina Bifida emerging in 1981 [10] . The current risk of all forms of MCMs with VPA is approximately 10% [11] . However, studies since 2009 in preschool children exposed in utero to VPA show that up to 30-40% experience delays in learning, speech, memory, motor and behavioral development [9, [12] [13] [14] [15] [16] [17] . In 2010, the Liverpool and Manchester Neurodevelopment Group (LMNDG) suggested that VPA demonstrates a dose-dependent relationship with developmental outcome and more recent evidence suggests that the risks are higher when VPA is taken with other AEDs as combination therapy [13, 17, 18] . Furthermore, the spectrum of developmental problems that children exposed to VPA in utero includes an increased risk of both autistic spectrum disorder and attention deficit/hyperactivity disorder (ADHD) compared with the general population [12, 13, 19] .
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children exposed to valproate in utero were at an increased risk of poorer neurodevelopmental scores compared to the general population [20] . However, it cautioned that VPA is still a very effective drug for some and that strict counselling should be in place to allow women with epilepsy (WWE) to make informed decisions.
In light of this new information about VPA, we aimed to determine how this affected prescribing practice in the Republic of Ireland in terms of the number of women of childbearing age taking VPA between 2008-2013, the time period during which the increased risks associated with the drug became clear and to further examine co-prescribing of folic acid 5 mg and contraceptives in order to see if prescribers, who had no option but to use VPA, were taking precautions against the known risks.
Monitoring prescribing practice for AEDs in Ireland
Residents in the Republic of Ireland can obtain prescribed medications through three different community drug schemes allowing for reasonably accurate monitoring of prescribing of VPA nationally in Ireland. General Medical Services or Medical Card Scheme (GMS) provides for free medicines on a means tested basis taking into account individual or family finances and age. The second scheme is on private prescription through the Drug Payment Scheme (DPS), whereby, medicines above a certain monthly payment threshold will be reimbursed by the state for out of pocket expenses above this threshold. The final scheme is the Long Term Illness (LTI) scheme which entitles a patient with one of 15 eligible illnesses, including epilepsy, to free medicines.
Because epilepsy is the only condition on the LTI scheme for which VPA is conventionally prescribed in over 16 year olds, and because the LTI scheme is not means tested, it is correct to assume that the LTI scheme provides a precise accounting of the national prescribing of VPA for epilepsy alone. The other schemes are more likely to reflect the mixed prescribing practice for VPA across the disease spectrums of epilepsy, bipolar disease and migraine. Unfortunately, it is not possible to deduce what level of specialisation the prescribers have in each scheme although the LTI prescribers, by virtue of the requirement for a confirmed diagnosis of epilepsy, are more likely to be neurologists.
Methods
Pharmacy claims data from the GMS, DPS and the LTI schemes were used. The details made available via the Health Service Executive (HSE)-primary care reimbursement services. The dispensing data contains demographic details on the patients (age, gender and location of residence), information on the medicine dispensed such as the drug name, strength and quantity of tablets/ capsules dispensed. No clinical or outcome data is available. All prescription items are coded using the WHO Anatomical Therapeutic Chemical (ATC) classification.
All prescriptions dispensed from community pharmacies from 2008 to 2013 inclusive were examined for women aged 16-44 years from all schemes. Numbers of prescriptions, and patients on drugs associated with epilepsy were identified using the ATC code N03. In particular, VPA was identified by code N03AG01. Percentage use and associated 95% confidence intervals are presented. Numbers of patients who received at least one prescription for VPA in 2013 were examined by urban and rural geographical residence for GMS and LTI schemes separately. Rates of prescribing per 1000 population of VPA by urban or rural geographical area of residence were calculated using the same total eligible female population aged 16-44 years from the 2011 Irish census for both the GMS and LTI eligible, to ensure comparability and for total rates to be calculated. These rates are presented with 95% confidence intervals using the Poisson method. In addition, we examined the co-prescription of folic acid 5 mg (ATC code B03BB) and oral contraceptives (ATC codes G03A)/IUD (G02AB03) in women receiving VPA in 2013. In Ireland, the 5 mg preparation of folic acid must be obtained on prescription so we do not have data on women who may be taking the 0.4 mg dose that is available over the counter.
All data analysis was conducted using SAS v9.3 and significance at p < 0.05 is assumed.
Results
The number of women who received VPA between the ages of 16-44 years in Ireland from 2008-2013 are shown in Fig. 1 The largest decline in VPA prescribing was in the Drug Payment Scheme (DPS) and which fell from a contribution of 9.3% (95%CI 5.0%, 13.5%) to 3.2% (95%CI 0, 7.5%) of all patients on VPA. There was a decline in the proportion of patients on VPA originating from the LTI scheme from 23.2% (95%CI 19.3%, 27.1%) to 20.8% (95%CI 16.9%, 24.7%) whereas there was a rise from 67.5% (95%CI 65.0%, 70.0%) to 76.0% (95%CI 73.9%, 78.2%) in the proportion of patients from the GMS. Fig. 1 presents the monthly trend in numbers on VPA over time comparing the LTI scheme (blue line), which is a precise trend of VPA prescribing in epilepsy only, versus the combined trend for the two other schemes (GMS and DPS-red line) which reflects prescribing across the range of indications for VPA (Epilepsy, Migraine, Bipolar Disease).
The percentage of women co-prescribed folic acid (5 mg) and oral/IUD contraceptives with VPA in 2013 is captured in Fig. 2 . The percentage of VPA in the LTI scheme co-prescribed folic acid is considerably higher than in the GMS medical card scheme (30% vs. 10%) which may reflect the varying conditions that the drug is being used for within the GMS scheme. The level of co-prescribed oral and IUD contraceptives is also low for those receiving VPA within the GMS scheme. The co-prescribing of contraceptives with VPA was not captured in the DPS and LTI scheme. Only those eligible for the GMS scheme have all their claims captured by the pharmacy as all medicines are reimbursable. Under the LTI and DPS schemes all medicines are not reimbursed so there is less certainty around capturing the use of contraception in these schemes. Table 1 presents the number of total eligible female population 16-44 years, and rates of VPA prescribing per 1000 population by urban and rural geographical area for the GMS and LTI schemes respectively. The results show that rates of VPA use are higher in rural compared to urban areas for both the GMS and LTI schemes respectively but only significantly higher for the GMS scheme. The results also show the much higher rates in the GMS scheme compared to LTI scheme.
Discussion
The first prevalence study of epilepsy completed in the Republic of Ireland reports a national lifetime prevalence of self-reported epilepsy among adults of 10 per 1,000 population, approximately 36,000 over the age of five years [21] ; it can be thus estimated that about 10,000 of these are women of childbearing potential [22] .
This study is the first of its kind to examine not only recent national trends in VPA prescribing in this group of women in light of emerging data about its teratogenic effects but also to examine VPA prescribing outside of epilepsy, the influence of geographical location and the co-prescribing of folic acid and oral contraceptives.
The main findings of this study are that between 2008 and 2013, when the evidence for particular risks of VPA in pregnancy were emerging internationally, the overall the rate of prescribing of VPA in the Republic of Ireland dropped from 3.5/1000 in 2008 to 3.14/1000 per eligible population in 2013. While this is positive, the downward trend was only clear in schemes where VPA was reliably being prescribed for epilepsy. Combining other reimbursement schemes showed VPA prescribing rates rising over the 5-year observation period. In these schemes VPA prescribing reflects a mixture of epilepsy, bipolar disorder, and migraine.
The relatively low prescribing of folic acid and contraception in all schemes especially the GMS where rates were both at or below 10%, suggests that VPA prescribing is not occurring as a 'last resort' due to therapeutic failures of alternative drugs since there appears to be little awareness of the potential dangers and possible mitigating measures.
The finding that there was a higher rate of VPA prescription in rural compared to urban areas for both the GMS and LTI schemes suggests that regardless of condition, an address distant from academic medical centers predicts a higher exposure to VPA. In relation to epilepsy, studies in Ireland have previously demonstrated limited knowledge and reluctance to augment AEDs amongst primary care practitioners [23, 24] . Epilepsy care in Ireland can often be fragmented and geographic influences are known to play a considerable role in quality, access and service delivery [25] [26] [27] [28] . None of this is conclusive but suggests a need for better outreach to rural healthcare networks by specialised practitioners at academic centres.
On November 21st 2014, The Coordination group for Mutual Recognition and Decentralized procedures (CMDh) of the European medicines agency ruled that ''Doctors in the EU are now advised not to prescribe VPA for epilepsy or bipolar disorder in pregnant women, in women who can become pregnant or in girls unless other treatments are ineffective or not tolerated. Those for whom VPA is the only option for epilepsy or bipolar disorder should be advised on the use of effective contraception and treatment should be started and supervised by a doctor experienced in treating these conditions. Women and girls who have been prescribed VPA should not stop taking their medicines without consulting their doctor as doing so could result in harm to themselves or to an unborn child'' [29] .
A small number of international studies have reported on the prescribing of VPA in both epilepsy and bipolar disease. In the UK, whose drug reimbursements schemes are similar to Ireland's, dramatic increases in prescribing of VPA in women of childbearing age (from 0% to 34%) were reported in a cohort of 4700 patients being treated for bipolar disease between 1995-2007 [30] . The UK general practice database, looking at AED prescribing for girls from 12 to 18 years between 1993 and 2006, demonstrated a decrease in VPA prescribing from 0.94 per 1000 to 0.63 per 1000 reflecting the longstanding increased concern amongst the epilepsy community in the teratogenic effects of VPA [31] .
In the US, a survey of de-identified data from the National Hospital and Ambulatory Medical Care Surveys (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) found that 83% of VPA prescriptions were issued to women without epilepsy and 74% of these were for psychiatric diagnoses. The prevalence of antiepileptic drug prescriptions among women without epilepsy tripled during the study period (10.3 [1996-1998] vs. 34.9 [2005-2007] per 1000 patient visits), whereas VPA prescriptions for epilepsy increased only slightly (3.1 [1996-1998] vs. 3.7 [2005-2007] per 1000 patient visits) [32] .
Finally, analysis of data from the Australian Register of AEDs in Pregnancy between the years 1999-2007 showed that prescribing of carbamazepine, phenytoin and VPA for pregnant women decreased over time. However, prescribing trends for VPA in the wider community increased possibly reflecting, as in our study, prescribing for psychiatric and other conditions [33] .
There are some limitations to our study. The data cannot define whether the women treated had any co-morbidities such as an intellectual disability. This may explain some of the low rates of co-prescribing of the OCP. During the period 2008-2013, Ireland underwent a massive financial readjustment with an associated increase in unemployment and increase in those eligible for the medical card (GMS) scheme based on financial hardship. Some of the increase in VPA prescribing may have been attributable to the growth in the numbers on the GMS scheme, but it is not possible separate out these figures from a real increase due to prescribing habits. Finally, it was not possible to determine the specialisation of the prescribers in each scheme, information that would have been beneficial in determining to whom information dissemination and education should be targeted. What is known is that the falling rates in the LTI scheme are probably due to a higher representation of neurologists and epileptologists than the other schemes. Historically, the number of neurologists in Ireland has been very low per head of population which inevitably leads to prescribing of medicines for neurological conditions by nonspecialist physicians. More recent expansion in recruitment since 2010 had enabled the numbers of neurologists to increase to a similar rate as the UK at one per 120,000 [34] but this is far below international norms (1/22,000 USA and 1/38,000 France). In conclusion; this study highlights the ongoing issue of the growth of prescribing for VPA in non-epilepsy populations despite warnings highlighting the risks of this medication in women of child bearing potential. Similar findings have been seen in the UK, USA and Australia. According to the European Medicines Agency and EHRA, VPA should no longer be considered as a first choice where pregnancy is considered. This study suggests, at least when it comes to epilepsy, rates of prescribing are falling even if the coprescribing of folic acid and contraceptives suggest that there is still a lot of work to be done. However, the rising rates of prescribing of VPA in mixed populations of patients highlighted in this study suggests the need for improved dissemination of information on prescribing risks amongst non-epilepsy specialists and patients and better outreach services to rural health practitioners to address the rural/urban divide.
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Highlights The risks of AED drugs in pregnant women have been known for many years: in particular the risks associated with VPA have burgeoned.
The European Medicines agency has suggested that VPA should no longer be prescribed for epilepsy in pregnant women or in women of childbearing potential unless other treatments are ineffective or not tolerated.
In Ireland between 2008 and 2013, the overall prescribing of VPA in women between 16 and 44 years has dropped, in particular, for those with epilepsy reflecting the epilepsy community's recognition of the risks.
There is evidence that prescribing is increasing for other indications such as bipolar disease and migraine suggesting that better dissemination of information about the risks may be required for practitioners and patients in these populations.
